Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Tesaro's Varubi: Safety, Dosing Convenience Could Drive Third NK-1 Inhibitor

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approval for prevention of chemotherapy induced nausea and vomiting in delayed phase after chemo paves way for fourth-quarter market entry.


Related Content

US FDA’s First Complete Response Letter Of 2017 Involves … Manufacturing


Related Companies